2ND LINE HORMONAL-THERAPY WITH AMINOGLUTETHIMIDE IN METASTATIC BREAST-CANCER

被引：10

作者：

BRUFMAN, G

BIRAN, S

机构：

[1] Department of Clinical Oncology, Hadassah University Hospital, Jerusalem

来源：

ACTA ONCOLOGICA | 1990年 / 29卷 / 06期

关键词：

Aminoglutethimide; Breast cancer; Tamoxifen;

D O I：

10.3109/02841869009092989

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide. The overall response rate was 34% and the median duration of response 9.5 months. Response to aminoglutethimide was achieved in all metastatic sites except lung and brain. Even 25% of patients who had failed to respond to prior tamoxifen did respond objectively to aminoglutethimide. The actuarial survival for all patients at 30 months was 22% Although initial toxicity was high (70% side effects of aminoglutethimide were transient, and treatment had to be discontinued in only four patients. The results of this trial confirm that aminoglutethimide is an effective treatment in metastatic breast cancer. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

收藏

页码：717 / 720

页数：4

相关论文

共 50 条

[21] DROLOXIFENE IN ADVANCED BREAST-CANCER AS 2ND-LINE OR 3RD-LINE ENDOCRINE THERAPY - A PHASE-II TRIAL [J].

ENGEL, E ;

KLEEBERG, UR ;

MARSCHNER, N ;

WANDER, HE ;

REICHEL, L ;

RAUSCHNING, W ;

EDLER, L .

ONKOLOGIE, 1992, 15 (05) :368-372

[22] SEQUENCE-THERAPY AND INTERVAL THERAPY IN METASTATIC BREAST-CANCER WITH TAMOXIFEN AND MPA [J].

MERKLE, E ;

BAHR, I ;

HENKE, A ;

BUHNER, M ;

LANG, N .

TUMORDIAGNOSTIK & THERAPIE, 1994, 15 (03) :104-108

[23] MITOXANTRONE AND MITOMYCIN-C AS 2ND-LINE TREATMENT FOR ADVANCED BREAST-CANCER [J].

REPETTO, L ;

MIGLIETTA, L ;

GARDIN, G ;

NASO, C ;

GIUDICI, S ;

MERLINI, L ;

QUEIROLO, P ;

CAMPORA, E ;

PRONZATO, P ;

ROSSO, R .

ANNALS OF ONCOLOGY, 1992, 3 (02) :165-166

[24] Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate [J].

Licchetta, A. ;

Correale, P. ;

Migali, C. ;

Remondo, C. ;

Francini, E. ;

Pascucci, A. ;

Magliocca, A. ;

Guarnieri, A. ;

Savelli, V. ;

Piccolomini, A. ;

Carli, A. F. ;

Francini, G. .

JOURNAL OF CHEMOTHERAPY, 2010, 22 (03) :201-204

[25] HORMONAL-THERAPY IN THE TREATMENT OF MANDIBULAR METASTASIS OF BREAST-CARCINOMA - REPORT OF A CASE [J].

EHLINGER, P ;

PEETERS, LC ;

SERVAIS, J ;

FOSSION, E .

INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 1993, 22 (02) :108-109

[26] Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer [J].

Toi, Masakazu .

BREAST CANCER, 2025, 32 (04) :619-620

[27] POTENTIAL FOR COST ECONOMIES IN GUIDING THERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER [J].

ROBERTSON, JFR ;

WHYNES, DK ;

DIXON, A ;

BLAMEY, RW .

BRITISH JOURNAL OF CANCER, 1995, 72 (01) :174-177

[28] HORMONAL RISK-FACTORS IN BREAST-CANCER [J].

KUTTENN, F ;

THALABARD, JC ;

PLU, G ;

MAUVAISJARVIS, P .

BULLETIN DU CANCER, 1990, 77 :S31-S38

[29] Shifting paradigms in hormonal therapy for breast cancer [J].

Grana, G .

CANCER BIOLOGY & THERAPY, 2004, 3 (09) :797-805

[30] MITOXANTRONE-VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER [J].

FERRERO, JM ;

PIVOT, X ;

NAMER, M ;

WENDLING, JL ;

FRENAY, M ;

FRANCOIS, E ;

HOCH, M ;

TEISSIER, E .

BULLETIN DU CANCER, 1995, 82 (03) :202-207

← 1 2 3 4 5 →